PRKAA2 and cancer: Zhong and colleagues (2016) explored the molecular mechanisms underlying the antitumorigenic properties of metformin and they identified that the treatment of cancer cells with both metformin and AICAR, AMPK-activating agent, drove an upregulation of Let-7 levels18.